Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide add-on to SGLT-2 inhibitors in type 2 diabetes mellitus
jRCT2080223487Phase 3Completed
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide 1.0 mg + SGLT-2 inhibitor with Placebo + SGLT-2 inhibitor (2 arms). Primary endpoints: Glycaemic control improvement and Body weight reduction. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223487.